Up to 80% of human malignancies include either gain-of-function or loss-of-function mutations in either the oncogenic Raf, Ras, Akt or PI3K signaling pathways or in the tumor-suppressor genes NF1, PTEN, or TSC [78]. Here, PTEN is linked to neoplasm.